{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T13:46:29Z","timestamp":1780667189723,"version":"3.54.1"},"reference-count":20,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2024,10,11]]},"DOI":"10.18632\/oncotarget.28659","type":"journal-article","created":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T12:53:07Z","timestamp":1728651187000},"page":"741-747","source":"Crossref","is-referenced-by-count":3,"title":["A case of adenosquamous pancreatic cancer with a KRAS G12C mutation with an exceptional response to immunotherapy"],"prefix":"10.18632","volume":"15","author":[{"given":"Murtaza","family":"Ahmed","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent K.","family":"Larson","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arsen","family":"Osipov","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (Division of Hematology-Oncology) Cedars Sinai Medical Center, Los Angeles, CA 90048, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilofer","family":"Azad","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21218, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hendifar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (Division of Hematology-Oncology) Cedars Sinai Medical Center, Los Angeles, CA 90048, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2024,10,11]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"7","author":"Jemal","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"2","doi-asserted-by":"publisher","first-page":"132","DOI":"10.4251\/wjgo.v7.i9.132","article-title":"Adenosquamous carcinoma of the pancreas: Molecular characterization of 23 patients along with a literature review","volume":"7","author":"Von Hoff","year":"2015","journal-title":"World J Gastrointest Oncol"},{"key":"3","doi-asserted-by":"publisher","first-page":"e2216199","DOI":"10.1001\/jamanetworkopen.2022.16199","article-title":"Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma","volume":"5","author":"Aran","year":"2022","journal-title":"JAMA Netw Open"},{"key":"4","article-title":"Pancreatic Adenocarcinoma, Version 2.2024","author":"National Comprehensive Cancer Network","year":"2024","journal-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines"},{"key":"5","doi-asserted-by":"publisher","first-page":"566","DOI":"10.21037\/jgo.2017.02.02","article-title":"Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer","volume":"8","author":"Sakamoto","year":"2017","journal-title":"J Gastrointest Oncol"},{"key":"6","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance Olaparib for Germline-Mutated Metastatic Pancreatic Cancer","volume":"38","author":"Alg\u00fcl","year":"2019","journal-title":"N Engl J Med"},{"key":"7","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.1200\/JCO.2017.72.3502","article-title":"Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma","volume":"3","author":"Borges","year":"2017","journal-title":"J Clin Oncol"},{"key":"8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2208470","article-title":"Sotorasib inp.G12C-Mutated Advanced Pancreatic Cancer","volume":"38","author":"Dahan","year":"2023","journal-title":"N Engl J Med"},{"key":"9","doi-asserted-by":"publisher","first-page":"1013902","DOI":"10.3389\/fonc.2022.1013902","article-title":"KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?","volume":"1","author":"Azmi","year":"2022","journal-title":"Front Oncol"},{"key":"10","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in Advanced Solid Tumors Harboring aMutation","volume":"4","author":"Pant","year":"2023","journal-title":"J Clin Oncol"},{"key":"11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability\/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study","volume":"3","author":"Gao","year":"2020","journal-title":"J Clin Oncol"},{"key":"12","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1200\/JCO.2018.78.2276","article-title":"T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028","volume":"3","author":"van Brummelen","year":"2019","journal-title":"J Clin Oncol"},{"key":"13","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.12998\/wjcc.v9.i13.2969","article-title":"Immunotherapy for pancreatic cancer","volume":"9","author":"Moon","year":"2021","journal-title":"World J Clin Cases"},{"key":"14","doi-asserted-by":"publisher","first-page":"e2100437","DOI":"10.1200\/PO.21.00437","article-title":"Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With GermlineMutation and High Tumor Mutation Burden: Case Report and Literature Review","volume":"6","author":"Ganju","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"15","doi-asserted-by":"publisher","first-page":"e13133","DOI":"10.7759\/cureus.13133","article-title":"A Case of Metastatic Pancreatic Adenocarcinoma in Complete Remission Using Chemotherapy and Immunotherapy","volume":"1","author":"Atiq","year":"2021","journal-title":"Cureus"},{"key":"16","doi-asserted-by":"publisher","first-page":"240","DOI":"10.14740\/jmc3918","article-title":"Survival Benefit of Pembrolizumab for Patients With Pancreatic Adenocarcinoma: A Case Series","volume":"1","author":"Lee","year":"2022","journal-title":"J Med Cases"},{"key":"17","doi-asserted-by":"publisher","first-page":"9926","DOI":"10.1002\/cam4.5700","article-title":"Pancreatic adenosquamous carcinoma: A population level analysis of epidemiological trends and prognosis","volume":"1","author":"Liao","year":"2023","journal-title":"Cancer Med"},{"key":"18","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1016\/j.prp.2018.10.006","article-title":"PD-L1 expression in pancreatic adenosquamous carcinoma: PD-L1 expression is limited to the squamous component","volume":"21","author":"Mihara","year":"2018","journal-title":"Pathol Res Pract"},{"key":"19","doi-asserted-by":"publisher","first-page":"46209","DOI":"10.1038\/srep46209","article-title":"PD-L1 expression in lung adenosquamous carcinomas compared with the more common variants of non-small cell lung cancer","volume":"7","author":"Liang","year":"2017","journal-title":"Sci Rep"},{"key":"20","doi-asserted-by":"publisher","first-page":"7207","DOI":"10.1002\/cam4.2580","article-title":"The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes","volume":"8","author":"Bian","year":"2019","journal-title":"Cancer Med"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28659","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T13:43:14Z","timestamp":1728654194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,11]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,10,11]]}},"alternative-id":["28659"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.28659","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,11]]}}}